Harkness Pharmaceuticals, Inc., is a privately-held development stage biopharmaceutical company focused on developing novel therapies for obesity. The Company has initiated detailed human clinical trials for its first product, an oral formulation of the peptide enterostatin for the treatment of obesity.

The Company was formed in 2003 and established its corporate headquarters in San Diego, CA, as well as an East Coast Office in Rochester, NY.

Key Personnel:

Timothy J. Wollaeger
Chief Executive Officer & Chairman

Peter C. M. McWilliams, Ph.D.
Director of Business Development, Director

Byron Rubin, Ph.D.
Founder, Chief Scientific Officer and Vice President of Research

Prof. Edward Dennis
Founder, Director